ClinicalTrials.gg
CompletedNCT02558374Updated Apr 6, 2018Results posted

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

A Phase 3 interventional study of AR-13324 Ophthalmic Solution 0.02% and Timolol Maleate Ophthalmic Solution 0.5% BID in Open-angle Glaucoma and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-06.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
708
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
2nd of 17
708 · median 85
Started
2015
the only one that year
Phase 3
5 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 5 in phase 3, and was the 5th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes
  3. Post-washout intraocular pressure >20mmHg and \<30mmHg in 1 or both eyes at 2 qualification visits
  4. Corrected visual acuity equivalent to 20/200
  5. Able to give and follow study instructions

Exclusion criteria

Exclusion Criteria:

  1. ocular disease
  2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles
  3. Unmedicated intraocular pressure ≥30mmHg
  4. Use of more than 2 ocular hypotensive medications within 30 days of screening
  5. Known to any component of the formulation
  6. Previous glaucoma surgery or refractive surgery
  7. Ocular trauma within 6 months prior to screening
  8. Any ocular surgery or non-refractive laser treatment within 3 months prior to screening
  9. Recent or current ocular infection or inflammation in either eye
  10. Used ocular medication in either eye of any kind within 30 days of screening
  11. Mean central corneal thickness >620µm at screening
  12. Any abnormality preventing reliable applanation tonometry of either eye
  13. Clinically significant abnormalities in lab tests at screening
  14. Known hypersensitivity or to beta-adrenoceptor antagonists
  15. Clinically significant systemic disease
  16. Participation in any study within 60 days prior to screening
  17. Used any systemic medication that could have a substantial effect in intraocular pressure within 30 days prior to screening
  18. Women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
708 participants (actual)

Study arms

  • Experimental
    AR-13324 Ophthalmic Solution 0.02% & placebo

    1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU)

    Drug: AR-13324 Ophthalmic Solution 0.02% · Other: Placebo

  • Active comparator
    Timolol Maleate Ophthalmic Solution 0.5% BID

    1 drop twice daily (BID) in the morning (AM) \& evening (PM) in both eyes (OU)

    Drug: Timolol Maleate Ophthalmic Solution 0.5% BID

Interventions

06

What researchers measure

Primary outcomes

  1. IOP (Intraocular Pressure)

    The primary efficacy outcome is mean IOP

    Time frame: 3 months

Secondary outcomes

  1. Extent of Exposure

    Exposure to study medication in days for all treatment groups

    Time frame: 6 months

07

Results

Posted Apr 6, 2018

Participant flow

Participants were recruited at 53 sites starting in September 2015

Participant flow — Overall Study
MilestoneAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Started351357
Completed243314
Not completed10843

Outcome measures

PrimaryIOP (Intraocular Pressure)

The primary efficacy outcome is mean IOP

Time frame:
3 months
Reported as:
Mean · mmHg
IOP (Intraocular Pressure)
mmHgAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Day 1, 0800 hours23.93 ± 2.44123.89 ± 2.318
Day 1, 1000 hours22.67 ± 2.82622.77 ± 2.565
Day 1, 1600 hours22.17 ± 2.85722.04 ± 2.708
Day 15, 0800 hours19.20 ± 3.83318.60 ± 3.396
Day 15, 1000 hours17.93 ± 3.67817.80 ± 3.237
Day 15, 1600 hours17.76 ± 3.52717.85 ± 3.102
Day 43, 0800 hours19.45 ± 3.92918.52 ± 3.316
Day 43, 1000 hours18.12 ± 3.56017.89 ± 3.157
Day 43, 1600 hours17.89 ± 3.43817.88 ± 3.356
Day 90, 0800 hours19.24 ± 3.88918.35 ± 3.196
Day 90, 1000 hours18.30 ± 3.63717.60 ± 3.173
Day 90, 1600 hours18.02 ± 3.64417.66 ± 3.080
SecondaryExtent of Exposure

Exposure to study medication in days for all treatment groups

Time frame:
6 months
Reported as:
Mean · days
Extent of Exposure
daysAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Extent of Exposure147.4 ± 54.47167.7 ± 36.40

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AR-13324 Ophthalmic Solution 0.02% & Placebo1/351 (0.3%)8/351 (2.3%)245/351 (69.8%)
Timolol Maleate Ophthalmic Solution 0.5% BID0/357 (0%)10/357 (2.8%)139/357 (38.9%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Bladder Cancer RecurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3510/357
Chronic Myeloid LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3510/357
Papillary Thyroid CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3510/357
Cardiac ArrestCardiac disorders1/3510/357
Myocardial InfarctionCardiac disorders1/3510/357
Transient Ischaemic AttackNervous system disorders1/3511/357
Gastric VolvulusGastrointestinal disorders1/3510/357
Hiatus HerniaGastrointestinal disorders1/3510/357
Bladder ProlapseRenal and urinary disorders1/3510/357
Cervical DysplasiaReproductive system and breast disorders1/3510/357
Most frequent other events
Most frequent other events
EventAR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BID
Conjunctival HyperaemiaEye disorders168/35133/357
Instillation Site PainGeneral disorders83/35192/357
Cornea VerticillataEye disorders86/3510/357
Conjunctival HaemorrhageEye disorders56/35111/357
Instillation Site ErythemaGeneral disorders36/3514/357
Vital Dye Staining Cornea PresentInvestigations34/35124/357
Lacrimation IncreasedEye disorders26/3515/357
Erythema of EyelidEye disorders26/3512/357
Vision BlurredEye disorders22/3514/357

Baseline characteristics

Age, Continuous
Age, Continuous(years)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDTotal
Mean64.1 ± 11.5564.5 ± 10.9764.3 ± 11.25
Sex: Female, Male
Sex: Female, Male(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDTotal
Female208237445
Male143120263
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDTotal
Hispanic or Latino8987176
Not Hispanic or Latino262270532
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.02% & PlaceboTimolol Maleate Ophthalmic Solution 0.5% BIDTotal
American Indian or Alaska Native000
Asian7613
Native Hawaiian or Other Pacific Islander011
Black or African American8475159
White259274533
More than one race011
Unknown or Not Reported101
08

Study locations

1 site
  • Aerie Pharmaceuticals
    Bedminster, New Jersey 07921, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 4 months after primary completion. A results delay was requested in Dec 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2015
First posted
Sep 24, 2015
Start
Sep 2015
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results delay requested
Dec 19, 2017
Results first posted
Apr 6, 2018
Last update
Apr 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02558374
Responsible party
Sponsor
First posted
Sep 24, 2015
Start date
Sep 2015
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Apr 6, 2018
Last update
Apr 6, 2018

Study contacts

Theresa Heah, MD
study director · Aerie Pharmaceuticals, Inc
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion